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Nonivasive diagnosis of cancer can be provided by molecular imaging using hybrid mo-
dality to obtain better sensitivity, specificity and depiction localization of the disease. In
this study, we developed a new molecular imaging agent, radiogadolinium(III)-DOTA-
PAMAM G3.0-trastuzumab in the form of 147Gd-DOTA-PAMAM G3.0-trastuzumab, that
can be both target-specific radiopharmaceutical in SPECT as well as targeted contrast agent
in MRI for the purpose of diagnosis of HER-2 positive breast cancer. 147Gd radionuclide
emits g-rays that can be used in SPECT modality, but because of technical constraint, 147Gd
radionuclide was simulated by its radioisotope, 153Gd. Gd-DOTA complex has also been
known as good MRI contrast agent. PAMAM G3.0 is useful to concentrate Gd-DOTA com-
pelexes in large quantities, thus minimizing the number of trastuzumab molecules used.
Trastuzumab is human monoclonal antibody that can spesifically interact with HER-2.
Synthesis of radiogadolinium(III)-DOTA-PAMAM G3.0-trastuzumab was initiated by
conjugating DOTA NHS ester ligand with PAMAM G3.0 dendrimer. The DOTA-PAMAM G3.0
produced was conjugated to trastuzumab molecule and labeled with 153Gd. Characteriza-
tion DOTA-PAMAM G3.0-trastuzumab immunoconjugate was performed using HPLC sys-
tem equipped with SEC. The formation of immunoconjugate was indicated by the shorter
retention time (6.82 min) compared to that of trastuzumab (7.06 min). Radiochemical purity
of radiogadolinium(III)-DOTA-PAMAM G3.0-trastuzumab was >99% after purification pro-
cess by PD-10 desalting column. Radiogadolinium(III)-DOTA-PAMAM G3.0-trastuzumab
compound was stable at room temperature and at 2e8 0C as indicated by its radiochem-
ical purity 97.6 ± 0.5%e99.1 ± 0.5% after 144 h storage.
Copyright © 2014, The Egyptian Society of Radiation Sciences and Applications. Production
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through noninvasive imaging at molecular level (molecular
imaging) can be provided bymagnetic resonace imaging (MRI),
computed tomography (CT) and nuclear medicine imaging
modalities, such as positron emission tomography (PET) and
single photon emission computed tomography (SPECT), of
course, using molecular imaging agents that are appropriate
with the target molecules expressed by cancer cells. Nuclear
medicine imaging modalities have high sensitivity and can
distinguish between malignancy and necrosis. However, the
spatial resolution of nuclear medicine imaging is low, so that
is unable to provide the anatomical image required to pre-
cisely localize lesions. On the other hand, MRI and CT mo-
dalities can provide excellent anatomic details, but have low
sensitivity, so do not provide functional details (Gambhir,
2007; Schillaci & Simonetti, 2004). This encourages the utiliz-
ing of PET-CT and SPECT-CT hybrid modalities. The main
advantages are better attenuation correction, increased
specificity, and accurate depiction of the localization of dis-
ease and possible involvement of adjacent tissues (Mariani
et al., 2010). Because of spatial resolution of MRI is much
higher compared to CT and because MRI only uses radio fre-
quencies, instead of ionizing radiations, the utilizing PET-MRI
and SPECT-MRI hybrid modalities in molecular imaging
research have been popular and are potential in clinical use
(Goetz, Breton, Choquet, Israel-Jost, & Constantinesco, 2008;
Pichler, Kolb, Nagele, & Schlemmer, 2010).
Function and performance of MRI and nuclear medicine
imaging in molecular imaging are determined by the appro-
priate biological interactions between molecular imaging
agents administered to the patients and target molecules
expressed by diseased cells. Molecular imaging agents for PET
and SPECT are stated as target-spesific radiopharmaceuticals,
whereas for MRI are called as targeted contrast agents. Ideally,
molecular imaging agent fot PET-MRI and SPECT-MRI hybrid
modalities is a single compound that acts both as target-
spesific radiopharmaceutical for PET or SPECT, and as tar-
geted contrast agent for MRI (Valliant, 2010).
Antigens and receptors are target molecules expressed by
cancer cells that become main focus associated to the use of
monoclonal antiody. Monoclonal antibodies are part of mo-
lecular imaging agents that have a major role in process of
biological interactions with the target molecules. Epidermal
growth factor receptor (EGFR) or human epidermal growth
factor receptor (HER) which is transmembrane tyrosine kinase
protein is an important receptor (the target molecule) because
it is recognized by monoclonal antibodies, and is also often
found overexpressed inmalignant cancers (Marmor, Skaria, &
Yarden, 2004). One family member of this receptor is HER-2,
that is also known as ErbB2, overexpressed in 25e30% of
breast cancer cases (Carlsson, 2008; Leonard et al., 2002).
One of the monoclonal antibodies that can spesifically
interact with HER-2 is tastuzumab, an IgG monoclonal anti-
body under the trade name Herceptin®. Herceptin® has been
routinely used for the treatment of HER-2 positive breast
cancer. The complement determinant region in variable
domain (Fv) in the molecule structure of trastuzumab have arole in recognizing epitope or binding site on extracellular
domain of HER-2 when immunotherapy process desired takes
place (Leonard et al., 2002).
Trastuzumab labeled with g-ray emitting radionuclides
can spesifically interact with HER-2 that is overexpressed in
HER-2 positive breast cancers. The g-ray radiation will be
detected by SPECT detector placed in the patient's body sur-
face, which is then displayed in the form of location of cancer
cells image that subsequently used for diagnosis (Tamura
et al., 2013). The same way is shown by trastuzumab conju-
gated with MRI contrast agents that is able enhance water
proton relaxation rate (1/T1) at surrounding area of interaction
of trastuzumab with HER-2. Enhancement proton relaxation
rate causes enhancement microwave intensity emitted and
captured by MRI detector, which is then displayed in the form
of brighter location image (Bellin, 2006).
Trastuzumab labeling with g-ray emitting radionuclides
for diagnostic purposes has been carried out by Perik et al.
(2006) and de Korte et al. (2007) by conjugating 111In-DTPA
with trastuzumab. 111In radionuclide decays by electron cap-
ture followed g-ray emission that can be detected by SPECT.
111In-DTPA-trastuzumab radiopharmaceutical wass used as
molecular imaging agent for noninvasive SPECT imaging that
was potential to HER-2 (Perik et al., 2006; de Korte et al., 2007),
although SPECT has limitation in spatial resolution (Gambhir,
2007).
This study developed a new molecular imaging agent,
radiogadolinium(III)-DOTA-PAMAM G3.0-trastuzumab in the
form of 147Gd-DOTA-PAMAM G3.0-trastuzumab that has dual
roles in SPECT-MRI hybrid modality for diagnosis of HER-2
positive breast cancer. 147Gd radionuclide which decays by
electron capture are g-ray emitting radionuclide (Eg¼ 229 keV,
t1/2 ¼ 38.1 h) that can be used in SPECT. But, due to technical
constraints, 147Gd radionuclide was simulated by its radio-
isotopes, 153Gd (Eg ¼ 102 keV; t1/2 ¼ 241.6 days). Gd-DOTA
complex has also been known as good MRI contrast agent.
Role of PAMAM G3.0 dendrimer is to concentrate Gd-DOTA
complex in large quantitites and to minimize the use of
expensive trastuzumab, so the molecular imaging agent dose
administered to the patient can be minimized without
reducing image quality as well as ensuring the safety related
the dose of Gd-DOTA that can be reduced considerably lower
than the LD50.
The aim of this study was to synthesize and test the sta-
bility of molecular imaging agent 147Gd-DOTA-PAMAM G3.0-
trastuzumab through simulation of 153Gd-DOTA-PAMAM
G3.0-trastuzumab which have dual roles as SPECT target-
spesific radiopharmaceuticals and as MRI targeted contrast
agents for diagnosis of HER-2 positive breast cancer.2. Methods
2.1. Materials and equipments
Materials used are trastuzumab (Herceptin®, Roche), poly-
amidoamine generation 3 (PAMAM G3.0) dendrimer with
ethylene diamine core and amine surface groups, dime-
thylformamide or DMF (SigmaeAldrich), 1,4,7,10-
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hydroxysuccinimide ester) or DOTA NHS ester (Macrocyclics),
NaCl, HCl, NaOH, ethylen diamine tetraacetic acid (EDTA),
dipotassium hydrogen phosphate, potassium dihydrogen
phosphate (Merck), sulfo-succinimidyl-4-(N-maleimidometh-
yl) cyclohexane 1-carboxylate or sulfo-SMCC, Traut's reagent
or 2-iminothiolane HCl (Thermo Scientific), sephadex G25
medium column, PD-10 desalting column (GE HealthCare),
standard protein, protein dye, Chelex-100 ion exchange resin
(Bio Rad), bovin serum albumin or BSA, 2 kD and 20 kD Mo-
lecular Weight Cut Off (MWCO) dialysis cassette (Thermo
Scientific), Instant Thin Layer Chromatography-Silica Gel or
ITLC-SG (Pall), size exclusion column (Agilent Bio SEC-3;
7.8  300 mm), gadolinium(III) oxide (Strem Chemicals),
153Gd prepared by irradiating natural Gd in a multipurpose
G.A. Siwabessy Reactor, National Nuclear Energy Agency of
Indonesia, Serpong.
Equipments used are thermomixer (Eppendorf), magnetic
stirrer (ColeeParmer), orbital shaker, water bath (Fisher Sci-
entific), microplate spectrophotometer (Biotek), water purifier
equipment (Sartorius), HPLC (Shimadzu) equipped with UV-
Visible detector and size exclusion column (Agilent),
gamma mini assay (DPC), dose calibrator (Biodex Medical
Systems).
2.2. Synthesis of radiogadolinium(III)-DOTA-PAMAM
G3.0-trastuzumab
2.2.1. Purification of trastuzumab
Trastuzumab (5 mg mL1) was purified from the excipients
using 20 kD MWCO dialysis cassette with 0.1 M phosphate
buffer saline (PBS) pH 7.4 (contains 5 mM EDTA and 1.2 g
Chelex-100 ion exchange resin). Dialysis was carried out for
3  24 h at 2e8 C. The concentration of purified trastuzumab
was measured using microplate spectrophotometer and was
characterized using HPLC equipped with size exclusion col-
umn, UV-Visible detector, and 0.01 M PBS pH 7.4 as mobile
phase.
2.2.2. Synthesis of DOTA-PAMAM G3.0-trastuzumab
immunoconjugate
2.2.2.1. Preparation and activation of DOTA-PAMAM G3.0
conjugate. DOTA NHS ester solution in 0.1 M phosphate buffer
pH 7.2 was reacted with PAMAM G3.0 dendrimer (molar ratio
96: 1). The pH of the mixture was adjusted to 7.2. The mixture
was then incubated for 24 h at 2e8 C.
DOTA-PAMAMG3.0 conjugate producedwas purified using
2 kDMWCO dialysis cassette with 0.05 M phosphate buffer pH
7.4 (contains 5 mM EDTA and 1.2 g Chelex-100 ion exchange
resin). Dialysis was carried out for 3  24 h at 2e8 C.
Purified DOTA-PAMAM G3.0 conjugate was then activated
by adding Traut's reagent solution (1 mg mL1) in phosphate
buffer 0.05M pH 7.4 (contains 5mM EDTA) into DOTA-PAMAM
G3.0 conjugate. The mixture was then incubated at room
temperature under N2 flow for 1 h.
Activated DOTA-PAMAMG3.0 conjugate was purified using
PD-10 desalting column which has been conditioned by BSA
and 0.1 M phosphate buffer pH 7.4 (contains 5 mM EDTA) as
eluent. Eluates was retrieved in 250 mL fraction with total of 40
fractions. Each fraction then was sampled and tested usingcolorimetric protein dye (1:4 in H2O). Positive fractions to the
colorimetric assay were collected.
2.2.2.2. Activation of trastuzumab. Sulfo-SMCC was dissolved
in a small volume of DMF, and diluted by adding 0.1 M PBS pH
7.4 (contains 5 mM EDTA) to obtain 1 mg mL1. The solution
was then added into purified trastuzumab. The mixture was
incubated for 1 h at room temperature followed by purifica-
tion using PD-10 desalting column which has been condi-
tioned by BSA and 0.1 M PBS pH 7.4 (contains 5 mM EDTA) as
eluent. Eluates was retrieved in 250 mL fraction with total of 40
fractions. Each fraction then was sampled and tested using
colorimetric protein dye (1:4 in H2O). Positive fractions to the
colorimetric assay were collected.
2.2.2.3. Preparation of DOTA-PAMAM G3.0-trastuzumab
immunoconjugate. Activated trastuzumab was added into
activated DOTA-PAMAM G3.0 conjugate. The mixture was
incubated for 24 h at 2e8 C. DOTA-PAMAMG3.0-trastuzumab
immunoconjugate produced was purified using 20 kD MWCO
dialysis cassette with 0.1 M phosphate buffer pH 7.4 (contains
1.2 g Chelex-100 ion exchange resin). Dialysis was carried out
for 4  12 h at 2e8 C.
Purified DOTA-PAMAM G3.0-trastuzumab immunoconju-
gate was then dispensed to the vials and stored at 2e8 C. This
immunoconjugate was characterized using HPLC equipped
with size exclusion column, UV-Visible detector, and 0.01 M
PBS pH 7.4 as mobile phase.
2.2.3. Labeling of DOTA-PAMAM G3.0-trastuzumab
immunoconjugate with 153Gd
2.2.3.1. Preparation 153GdCl3. 50 mg Gd2O3 was irradiated in a
multipurpose G.A. Siwabessy Reactor (National Nuclear En-
ergy Agency of Indonesia) for four days. Irradiated Gd2O3 was
dissolved in 5 mL of 2 N HCl.
2.2.3.2. Labeling process. Aliquots of DOTA-PAMAM G3.0-
trastuzumab immunoconjugate in 0.1 M phosphate buffer
pH 7.4 was reactedwith GdCl3 in the same buffer solution. The
mixture was adjusted by adding 0.1 M NaOH to pH 7, then
incubated at 37 C. An excess of 0.05 M EDTA solution (molar
ratio EDTA: 153Gd¼ 20: 1) was added at the end of the reaction,
followed by incubating at 37 C for 10 min. Optimization of
reaction time was carried out at 2e8 C.
Labeling percentage of 153Gd on DOTA-PAMAM G3.0-
trastuzumab was determined using ITLC-SG strip
(1 cm  10 cm) as stationary phase and saline solution as
mobile phase. Labeling percentage was obtained by
comparing the counts under peak of 153Gd-DOTA-PAMAM
G3.0-trastuzumab to the total counts.
Purification of 153Gd-DOTA-PAMAM G3.0-trastuzumab was
carried out using PD-10 desalting column which has been
conditioned by BSA and 0.1 M PBS pH 7.4 as eluent. Eluates
was retrieved in 250 mL fraction with total of 40 fractions. Each
fraction was scanned using gamma mini assay. The fractions
had high radioactivities was analyzed using the TLC system to
determine the radiochemical purity.
2.2.3.3. Nonspesific binding test of PAMAM G3.0. PAMAMG3.0
solution in 0.1 M phosphate buffer pH 7.4 was reacted with
Fig. 1 e Synthesis reaction scheme: A. DOTA-PAMAM G3.0-sulfhydryl B. Trastuzumab-maleimide; C. DOTA-PAMAM G3.0-
trastuzumab; D. 153Gd-DOTA-PAMAM G3.0-trastuzumab.
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7, and incubated at the same condition with the labeling of
DOTA-PAMAM G3.0-trastuzumab with 153Gd.
An excess of 0.05 M EDTA solution (molar ratio EDTA:
153Gd¼ 20: 1) was added at the end of the reaction, followed by
incubating at 37 C for 10 min. The mixture was loaded onto
PD-10 desalting column which has been conditioned by BSA
and 0.1 M PBS pH 7.4 as eluent. Eluates was retrieved in 250 mL
fraction with total of 40 fractions. Each fraction was scanned
using gamma mini assay. The fractions had high radioactiv-
ities was analyzed using the TLC system to determine the
radiochemical purity.
2.2.3.4. Nonspesific binding test of trastuzumab. Trastuzumab
solution in 0.1 M phosphate buffer pH 7.4 was reacted with
153Gd. The mixture was adjusted by adding 0.1 M NaOH to pH
7, was then incubated at the same condition with the labeling
of DOTA-PAMAM G3.0-trastuzumab with 153Gd.
An excess of 0.05 M EDTA solution (molar ratio EDTA:
153Gd¼ 20: 1) was added at the end of the reaction, followed by
incubating at 37 C for 10 min. The mixture was loaded onto
PD-10 desalting column which has been conditioned by BSA
and 0.1 M PBS pH 7.4 as eluent. Eluates was retrieved in 250 mL
fraction with total of 40 fractions. Each fraction was scanned
using gamma mini assay. The fractions had high radioactiv-
ities was analyzed using the TLC system to determine the
radiochemical purity.2.3. Stability test of radiogadolinium(III)-DOTA-
PAMAM G3.0-trastuzumab
Stability test of radiogadolinium(III)DOTA-PAMAM G3.0-
trastuzumab was carried out at room temperature and at
2e8 C. The radiochemical purity was the analyzed using
ITLC-SG as stationary phase and saline solution as mobile
phase on 0, 48, 72, and 144 h.Fig. 2 e Purification fractions of: A. Activated DOTA-
PAMAM-sulfhydryl; B. Activated trastuzumab-maleimide
using colorimetric method.3. Results and discussion
Synthesis of radiogadolinium(III)-DOTA-PAMAM G3.0-
trastuzumab in the form of 147Gd-DOTA-PAMAM G3.0-
trastuzumab through simulation 153Gd-DOTA-PAMAM G3.0-
trastuzumab, as SPECT-MRI molecular imaging agent for
diagnosis of HER-2 positive breast cancer, was carried out in
several stages of the reaction (Fig. 1): a) the preparation and
activation of DOTA-PAMAM G3.0 conjugate using Traut's re-
agent; b) activation of trastuzumab using sulfo-SMCC; c)
conjugation of activated DOTA-PAMAM G3.0 to activated
trastuzumab; d) labeling of DOTA-PAMAM G3.0-trastuzumab
immunoconjugate with 153Gd.
The first reaction was conjugation of DOTA NHS ester
ligand with PAMAM G3.0 dendrimer to form DOTA-PAMAM
G3.0 conjugate (Fig. 1A). NHS ester-containing reagents react
with nucleophiles by releasing the NHS leaving group to form
an acylated product (Hermanson, 2008). The reaction of DOTA
NHS ester ligand with PAMAM G3.0 dendrimer containing 32
primary amine groups yields DOTA-PAMAM G3.0 conjugate
through stable amide bonds.By adjusting the molar ratio of NHS ester ligand to target
molecule, the level of modification and conjugation can be
controlled to create an optimal product (Hermanson, 2008). In
this study,molar ratio of DOTANHS ester to PAMAMG3.0 used
was 96: 1 or three folds of the number primary amines in
PAMAM G3.0 to obtain an optimal DOTA-PAMAM G3.0 conju-
gate, one molecule of PAMAM G3.0 could binds DOTA mole-
cules in the maximum amounts.
DOTA-PAMAM G3.0 conjugate formed was then activated
using Traut's reagent to create DOTA-PAMAM G3.0-sulfhydryl
(Fig. 1A). This thiolation reaction introduce reactive sulfhydryl
group at one end of target molecules. The sulfhydryl group is
employed to direct the conjugation reaction to a particular
part of a target macromolecule (Hermanson, 2008), in this
study, the macromulecule is trastuzumab.
Sulfhydryl groups are susceptible to oxidation and forma-
tion of disulfide crosslinks. To prevent disulfide bond forma-
tion, activation reaction of DOTA-PAMAM G3.0 conjugate
using Traut's reagent was carried out under nitrogen gas flow
to remove oxygen. In addition, EDTA (0.01e0.1 M) may be
added to buffers to chelate metal ions, preventing metal-
catalyzed oxidation of sulfhydryls (Hermanson, 2008).
Traut's reagent reacts with primary amine in the range of
pH 7e10, but its half-life in solution decreases as the pH in-
creases. Protein modification with Traut's reagent is very
efficient and proceeds rapidly at slightly basic pH
(Hermanson, 2008).
DOTA-PAMAM G3.0-sulfhydryl was purified using PD-10
desalting column with 0.1 M phosphate buffer containing
5 mM EDTA as eluent. The eluate fractions was sampled and
tested by protein dye. The fractions containing DOTA-PAMAM
G3.0-sulfhydryl was blue, while the fractions containing no
DOTA-PAMAM G3.0-sulfhydryl was brown like origin color of
protein dye. Colorimetric assay by protein dye showed the
fractions 10e17 containing DOTA-PAMAM G3.0-sulfhydryl
(Fig. 2A). The fractions were then collected to be used in
next step reaction.
The second reaction was activation of trastuzumab using
sulfo-SMCC to form trastuzumab-maleimide (Fig. 1B). The
NHS ester end of the reagent can react with primary amine
Fig. 3 e HPLC chromatograms of: A. Trastuzumab; B. DOTA-PAMAM G3.0-trastuzumab; C. Water; using SEC (stationary
phase) and 0.01 M PBS pH 7.4 (mobile phase).
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2008). Trastuzumab-maleimide was purified using PD-10
desalting column with 0.1 M PBS containing 5 mM EDTA
as eluent. The eluate fractions was sampled and tested byFig. 4 e Radiochromatogram of reagents involved in labeling D
153Gd.protein dye. Colorimetric assay by protein dye showed the
fractions 12e16 containing trastuzumab-maleimide
(Fig. 2B). The fractions were then collected to be used in
next step.OTA-PAMAM G3.0-trastuzumab immunoconjugate with
Fig. 5 e Radiochromatogram of 153Gd-DOTA-PAMAM G3.0-
trastuzumab purification.
Fig. 7 e Radiochromatogram of nonspesific binding test of
153Gd to PAMAM G3.0 (A) and to trastuzumab (B).
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sulfhydryl with trastuzumab-maleimide to generate DOTA-
PAMAM G3.0-trastuzumab immunoconjugate (Fig. 1C). The
double bond of maleimides that activated trastuzumab may
undergo an alkylation reaction with sulfhydryl groups of
DOTA-PAMAMG3.0-sulfhydryl to form stable thioether bonds.
This reaction is spesific in the pH range 6.5e7.5 (Hermanson,
2008). DOTA-PAMAM G3.0-trastuzumab immunoconjugate
formed was then purified using 20 kD MWCO dialysis cassette
with 0.1 M phosphate buffer pH 7.4 containing 1.2 g Chelex-
100 ion exchange resin.
DOTA-PAMAM G3.0-trastuzumab immunoconjugate was
charactrized using HPLC equipped with SEC, UV detector at
280 nm. Eluent used was 0.01 M PBS pH 7.4 with flow rate of
0.8 mL min1. The chromatogram obtained was compared to
the trastuzumab which also characterized with the same
HPLC system (Fig. 3).
The retention time of trastuzumab was 7.06 min, whereas
DOTA-PAMAM G3.0-trastuzumab immunoconjugate's was
6.82 min. The difference of trastuzumab's retention time
compared to DOTA-PAMAM G3.0-trastuzumab immuno-
conjugate showed that there is an increasing of the product's
molecular weight, thus smaller molecules of trastuzumab
difused to column pores as they passed through the column,
while larger molecules of the immunoconjugate remained inFig. 6 e Radiochromatogram of fractiinterstitial space and flowed rapidly down the length of the
column because they could not reside inside the pores. Larger
molecules will be eluted first (Wu, 1995).
Labeling was carried out by adding 153GdCl3 to DOTA-
PAMAM G3.0-trastuzumab immunoconjugate with molar
ratio 30:1 to form 153Gd-DOTA-PAMAM G3.0-trastuzumab
(Fig. 1D). Forming reaction of Gd-DOTA complex was carried
out at pH 7 (Bryant et al., 1999; Hak et al., 2009). At the end of
reaction, EDTA was added in excess to bind free 153Gd which
was not bound to DOTA-PAMAM G3.0-trastuzumab
immunoconjugate.on 13 and 24 using TLC system.
Table 1 e Temperature and time optimization of labeling
reaction of DOTA-PAMAM G3.0-trastuzumab
immunoconjugate with153Gd.
Temperature
37 C 2e8 C
Time Labeling
percentage (%)
Time Labeling
percentage (%)
1 h 24.8 ± 1.5 1 h 11.9 ± 0.2
2 h 37.1 ± 0.4 2 h 20.7 ± 0.9
3 h 50.8 ± 0.5 3 h 23.6 ± 1.4
5 h 53.3 ± 2.8 4 h 28.5 ± 0.4
16 h 58.7 ± 0.7 24 h 41.4 ± 0.2
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trastuzumab was determined using ITLC-SG strip and saline
solution (Table 1). This method was adopted from previous
studies concerning the labeling DOTA-trastuzumab immu-
noconjugate with 177Lu by Humani, Ramli, Rustendi, and
Subur (2010) and Ramli et al. (2011). The radiochromatogram
of 153Gd-DOTA-PAMAM G3.0-trastuzumab and the reagents
involved shown in Fig. 4.
Labeling DOTA-F(ab0)24.1 immunoconjugate with
153GdCl3
was carried out by Ramakrishnan et al. (2008) at 37 C for 16 h.
Higher labeling percentage was obtained at 37 C than at
2e8 C. This condition was not time dependent. In this work
weminimized the heating time to prevent structural damage,
and the labeling process was carried out at 37 C for 3 h.
Purification of 153Gd-DOTA-PAMAM G3.0-trastuzumab was
carried out by PD-10 desalting column to obtain radiochemical
purity of 95% as requirement for good molecular imaging
agent. Each fraction of eluate was counted its radioactivity
and was plotted (Fig. 5). The first peak at chromatogram was
predicted to be 153Gd-DOTA-PAMAM G3.0-trastuzumab
molecule and the second peak was 153Gd-EDTA. Both peaks
(fraction 13 and 24) was analyzed using TLC system to deter-
mine the radiochemical purity.
Rf of fraction 13 was zero (Fig. 6) indicated the presence of
153Gd-DOTA-PAMAM G3.0-trastuzumab molecule with the
radiochemical purity of 99.5%.Meanwhile, the Rf of fraction 24
was one indicated the presence of 153Gd-EDTA molecule.
Peak area of 153Gd-DOTA-PAMAM G3.0-trastuzumab
molecule included fraction 10e18 (Fig. 5). Radiochemical pu-
rity analysis of that fractions using TLC system showed that
the fractions 10-17 had radiochemical purity of 95%.
In this labeling process, we performed additional assays
that were (1) nonspesific binding test of 153Gd to PAMAM G3.0
and (2) 153Gd to trastuzumab. Results were shown in Fig. 7A
and B that showed radioactivity peak was at fraction 24. This
fraction was area peak of 153Gd-EDTA molecule as describedTable 2 e Stability test result of 153Gd-DOTA-PAMAM
G3.0-trastuzumab.
Time (hour) Radiochemical purity (%)
Room temperature 2e8 C
0 99.1 ± 0.5 99.1 ± 0.5
48 98.1 ± 0.7 99.0 ± 0.7
72 97.4 ± 0.8 98.9 ± 0.4
144 97.6 ± 0.5 98.2 ± 0.8previously in the purification of radioimmunoconjugate
(Fig. 5). In the nonspesific binding test of 153Gd to PAMAMG3.0,
fractions 10e17 was positive to protein dye assay, but did not
have radioactivity peak as shown at Fig. 7A. In the nonspesific
binding test of 153Gd to trastuzumab, fractions 10e15 was
positive to protein dye assay, but did not have radioactivity
peak as shown at Fig. 7B. This data showed that there were no
nonspesific binding of 153Gd to PAMAMG3.0 as well as 153Gd to
trastuzumab.
Molecular imaging agent should be stable, still intact, not
degradated during storage. Stability test of 153Gd-DOTA-
PAMAM G3.0-trastuzumab was carried out in storage at room
temperature and at 2e8 C. The test was analyzed by TLC
system on 0, 48, 72, and 144 h Table 2 showed 153Gd-DOTA-
PAMAM G3.0-trastuzumab was stable, relatively intact, with
radiochemical purity of respectively 97.6 ± 0.5% and
98.2 ± 0.8% at room temperature and at 2e8 C after 144 h of
storage. This result was similar to that reported by Nwe,
Bernando, Regino, Williams, and Brechbiel (2010), which
stated Gd-DOTA complex was very chemically stable.4. Conclusion
Synthesis radiogadolinium(III)-DOTA-PAMAM G3.0-
trastuzumab as SPECT-MRI molecular imaging agent for
diagnosis of HER-2 positive breast cancer had been success-
fully carried out. DOTA-PAMAM G3.0-trastuzumab immuno-
conjugate as precursor of radiogadolinium(III)-DOTA-PAMAM
G3.0-trastuzumab had been successfully formed as shown by
characterization using HPLC system equipped with SEC.
Radiogadolinium(III)-DOTA-PAMAM G3.0-trastuzumab com-
pound was stable at room temperature and at 2e8 C.
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